| Indication | Project code | Discovery | Non-Clinical | Phase I | Phase II | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lead | CDR optimization & Candidate |
Cell line & Process development |
||||||||
| Cancer | APB-A001 | |||||||||
| Project code | Target combinatory Therapy |
Discovery | Non-Clinical | Phase I | Phase II |
|---|---|---|---|---|---|
| APB-A001 | Chemotherapy | ||||
| Immunotherapy | |||||
| Radiotherapy | |||||
| Indication | Project code | Discovery | Non-Clinical (GLP-Toxicity) |
Phase I | Phase II | ||
|---|---|---|---|---|---|---|---|
| Lead | Candidate | Cell line & Process development |
|||||
| Cancer | APB-B001 | ||||||
| APB-B002 | |||||||